{"filing":{"accession_number":"0001628280-26-048377","cik":"0000001800","ticker":"ABT","company_name":"ABBOTT LABORATORIES","form":"8-K","filing_date":"2026-07-16","report_date":null,"primary_document":"abt-20260716.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828026048377/abt-20260716.htm"},"events":[{"id":18284,"run_id":16432,"accession_number":"0001628280-26-048377","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Abbott disclosed its second-quarter 2026 financial results on July 16, 2026, including reported sales growth of 13.0%, comparable sales growth of 4.8%, GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.31. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45–$5.60. This is a standard quarterly earnings release furnished as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).","company_name":"ABBOTT LABORATORIES","ticker":"ABT","filing_date":"2026-07-16","form":"8-K","submitted_at":null,"items":[{"id":17048,"accession_number":"0001628280-26-048377","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Abbott disclosed its second-quarter 2026 financial results on July 16, 2026, including reported sales growth of 13.0%, comparable sales growth of 4.8%, GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.31. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45–$5.60. This is a standard quarterly earnings release furnished as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:37:38.588184+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17048,"accession_number":"0001628280-26-048377","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"Abbott disclosed its second-quarter 2026 financial results on July 16, 2026, including reported sales growth of 13.0%, comparable sales growth of 4.8%, GAAP diluted EPS of $0.53, and adjusted diluted EPS of $1.31. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45–$5.60. This is a standard quarterly earnings release furnished as Exhibit 99.1, filed under Item 2.02 (Results of Operations and Financial Condition).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-16T11:37:38.588184+00:00","company_name":"ABBOTT LABORATORIES","ticker":"ABT","filing_date":"2026-07-16"}]}